Antisense Therapeutics has been granted a U.S. patent covering its ATL1102 drug in the treatment of multiple sclerosis.
The patent extends coverage of the ATL1102 compound for the treatment of relapsing-remitting multiple sclerosis patients until 2029 with the potential for up to a five year extension to 2034.
Antisense also has patent applications under examination in Europe, Japan, Canada, and Australia.
Additional patent protection in relation to the antisense technology and manufacturing is also provided internationally for ATL1102 by Antisense's technology partner Isis Pharmaceuticals.
A previous phase two study has confirmed the drug's activity in potently suppressing brain lesions in relapsing-remitting multiple sclerosis patients....... Read More - http://www.ms-uk.org/index.cfm/ATL1102